Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 - Episode 1

Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification

June 28, 2024

Guillermo Garcia-Manero, MD, Rami Komrokji, MD, Esther Natalie Oliva, MD , Amer Zeidan, MBBS, MHS, Thomas Cluzeau, MD, PhD

The expert panel in hematology examines recent WHO and ICC guideline updates, evaluating their impact on the evolving treatment landscape for myelodysplastic syndromes.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

Now Viewing

EP. 1: Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification

EP. 2: Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS 

EP. 3: Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies

EP. 4: Review of the COMMANDS Trial

EP. 5: Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial

EP. 6: Clinical Implications of COMMANDS Trial in Clinical Practice

EP. 7: Treatment Decision-Making Based on the COMMANDS Trials

EP. 8: Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024

EP. 9: Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data

EP. 10: Safety Profile of Available Frontline Treatments LR-MDS

EP. 11: 1L treatment of lower-risk MDS beyond luspatercept

EP. 12: Sequencing Second-Line Treatments for LR-MDS

EP. 13: Perspectives of IMerge Study

EP. 14: Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024

EP. 15: EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates

EP. 16: Final Thoughts on EHA 2024 Data for Lower-Risk MDS

Dr Garcia-Manero to Panel: How have the updates to WHO (Garcia-Manero G. Am J Hematol. 2023) and ICC guidelines impacted how you identify, diagnose, and classify myelodysplastic syndromes?